二盐酸1,3-苯并二噁唑-5,6-二胺 | 81864-15-5

• 物质功能分类: 分析化学 - 分析试剂 - 常用分析试剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 中文名称: 二盐酸1,3-苯并二噁唑-5,6-二胺
• 中文别名: 1,3-苯并间二氧杂环戊烯-5,6-二胺双盐酸盐；4,5-亚甲二氧基-1,2-苯二胺二盐酸盐；1,2二氨基-4,5-亚甲基二氧苯,盐酸盐；1,2二氨基-4,5-亚甲基二氧苯盐酸盐；1,2-二氨基-4,5-亚甲二氧基苯,二盐酸盐；1,2二氨基- 4,5 -亚甲基二氧苯,盐酸盐
• 英文名称: 1,3-Benzodioxole-5,6-diamine dihydrochloride
• 英文别名: 1,3-benzodioxole-5,6-diamine;dihydrochloride
• CAS: 81864-15-5
• 化学式: C7H10Cl2N2O2
• 分子量: 225.07
• InChiKey: YXEJRYIEFFUUID-UHFFFAOYSA-N

物化性质

• 熔点：
  247-249 °C
• 溶解度：
  H2O中可溶50mg/mL

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2932999099

文献信息

• ENGINEERED INTRACELLULAR SIALYLATION PATHWAYS
  申请人：THE UNIVERSITY OF WYOMING

  公开号：US20140024812A1

  公开（公告）日：2014-01-23

  Methods for manipulating carbohydrate processing pathways in cells of interest are provided. Methods are directed at manipulating multiple pathways involved with the sialylation reaction by using recombinant DNA technology and substrate feeding approaches to enable the production of sialylated glycoproteins in cells of interest. These carbohydrate engineering efforts encompass the implementation of new carbohydrate bioassays, the examination of a selection of insect cell lines and the use of bioinformatics to identify gene sequences for critical processing enzymes. The compositions comprise cells of interest producing sialylated glycoproteins. The methods and compositions are useful for heterologous expression of glycoproteins.

  提供了一种操作感兴趣细胞中碳水化合物处理途径的方法。该方法旨在通过利用重组DNA技术和底物供应方法来操纵与唾液酸化反应有关的多个途径，从而使感兴趣细胞中产生唾液酸化糖蛋白。这些碳水化合物工程努力包括实施新的碳水化合物生物测定方法，检查一系列昆虫细胞系，并利用生物信息学来鉴定关键处理酶的基因序列。这些组成部分包括产生唾液酸化糖蛋白的感兴趣细胞。这些方法和组成物对于异源表达糖蛋白非常有用。
• [EN] MULTIVALENT LIPOSOME FORMULATIONS<br/>[FR] COMPOSITIONS À BASE DE LIPOSOMES MULTIVALENTS
  申请人：DRAPER LAB CHARLES S

  公开号：WO2014116723A1

  公开（公告）日：2014-07-31

  This disclosure provides compositions, kits, and methods useful for treating or preventing viral and bacterial infection and reducing or preventing the effects of toxins. The methods comprise administering to a subject an effective amount of a liposomal composition.

  本披露提供了用于治疗或预防病毒和细菌感染以及减轻或预防毒素作用的组合物、试剂盒和方法。该方法包括向受试者施用有效量的脂质体组合物。
• Sialic acid producing bacteria
  申请人：Nestec S.A.

  公开号：EP2183984A1

  公开（公告）日：2010-05-12

  The present invention generally relates to the field of sialic acids, in particular to the field of sialic acid enriched food products and their uses. One embodiment of the present invention relates to a food product enriched with food-grade sialic acid producing bacteria and/or a fraction thereof containing sialic acid.

  本发明一般涉及硅烷酸领域，特别是富含硅烷酸的食品及其用途领域。本发明的一个实施方案涉及一种富含食品级硅烷酸生产菌和/或其含有硅烷酸的部分的食品。
• Antibody composition with altered Fab sialylation
  申请人：CSL Behring AG

  公开号：EP2233499A1

  公开（公告）日：2010-09-29

  The present invention relates to a population of antibodies enriched from an antibody preparation, wherein the enriched population of antibodies has an altered amount of sialylation in the Fab region of the antibodies as compared to the antibody preparation prior to enrichment. Furthermore, the present invention relates to a method of enriching a population of antibodies from an antibody preparation, wherein the enriched population of antibodies has an altered amount of sialylation in the Fab region of the antibodies as compared to the antibody preparation prior to enrichment. The present invention also relates to the population of antibodies of the invention for use in medicine, a pharmaceutical composition comprising the populations of antibodies of the invention and the use of the population of antibodies of the invention in the prevention and/or treatment of atherosclerosis, cancer and infections such as bacterial, viral or fungal infections.

  本发明涉及一种从抗体制备物中富集的抗体群，其中与富集前的抗体制备物相比，富集的抗体群具有改变的抗体 Fab 区的硅烷基化量。此外，本发明还涉及一种从抗体制备物中富集抗体群的方法，其中富集的抗体群与富集前的抗体制备物相比，抗体 Fab 区的硅烷基化量有所改变。本发明还涉及用于医药的本发明抗体群、包含本发明抗体群的药物组合物以及本发明抗体群在预防和/或治疗动脉粥样硬化、癌症和感染（如细菌、病毒或真菌感染）中的应用。
• Compositions and methods for producing a composition
  申请人：Bristol-Myers Squibb Company

  公开号：EP2253644A1

  公开（公告）日：2010-11-24

  The invention further provides for methods for mass-producing CTLA4-Ig from mammalian cells capable of producing this recombinant protein, and for purifying the CTLA4-Ig.

  本发明进一步提供了从能够产生 CTLA4-Ig 重组蛋白的哺乳动物细胞中大量生产 CTLA4-Ig 的方法，以及纯化 CTLA4-Ig 的方法。